Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology</title><author><name sortKey="An, Fei Fei" sort="An, Fei Fei" uniqKey="An F" first="Fei-Fei" last="An">Fei-Fei An</name><affiliation><nlm:aff id="A1">Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, 413 E 69th St, New York, NY, 10065</nlm:aff></affiliation></author><author><name sortKey="Chan, Mark" sort="Chan, Mark" uniqKey="Chan M" first="Mark" last="Chan">Mark Chan</name></author><author><name sortKey="Kommidi, Harikrishna" sort="Kommidi, Harikrishna" uniqKey="Kommidi H" first="Harikrishna" last="Kommidi">Harikrishna Kommidi</name></author><author><name sortKey="Ting, Richard" sort="Ting, Richard" uniqKey="Ting R" first="Richard" last="Ting">Richard Ting</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27223168</idno><idno type="pmc">4958516</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958516</idno><idno type="RBID">PMC:4958516</idno><idno type="doi">10.2214/AJR.16.16181</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">003702</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003702</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology</title><author><name sortKey="An, Fei Fei" sort="An, Fei Fei" uniqKey="An F" first="Fei-Fei" last="An">Fei-Fei An</name><affiliation><nlm:aff id="A1">Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, 413 E 69th St, New York, NY, 10065</nlm:aff></affiliation></author><author><name sortKey="Chan, Mark" sort="Chan, Mark" uniqKey="Chan M" first="Mark" last="Chan">Mark Chan</name></author><author><name sortKey="Kommidi, Harikrishna" sort="Kommidi, Harikrishna" uniqKey="Kommidi H" first="Harikrishna" last="Kommidi">Harikrishna Kommidi</name></author><author><name sortKey="Ting, Richard" sort="Ting, Richard" uniqKey="Ting R" first="Richard" last="Ting">Richard Ting</name></author></analytic><series><title level="j">AJR. American journal of roentgenology</title><idno type="ISSN">0361-803X</idno><idno type="eISSN">1546-3141</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>OBJECTIVE</title><p id="P1">The purpose of this article is to summarize advances in PET fluorescence resolution, agent design, and preclinical imaging that make a growing case for clinical PET fluorescence imaging.</p></sec><sec id="S2"><title>CONCLUSION</title><p id="P2">Existing SPECT, PET, fluorescence, and MRI contrast imaging techniques are already deeply integrated into the management of cancer, from initial diagnosis to the observation and management of metastases. Combined positron-emitting fluorescent contrast agents can convey new or substantial benefits that improve on these proven clinical contrast agents.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">7708173</journal-id><journal-id journal-id-type="pubmed-jr-id">377</journal-id><journal-id journal-id-type="nlm-ta">AJR Am J Roentgenol</journal-id><journal-id journal-id-type="iso-abbrev">AJR Am J Roentgenol</journal-id><journal-title-group><journal-title>AJR. American journal of roentgenology</journal-title></journal-title-group><issn pub-type="ppub">0361-803X</issn><issn pub-type="epub">1546-3141</issn></journal-meta><article-meta><article-id pub-id-type="pmid">27223168</article-id><article-id pub-id-type="pmc">4958516</article-id><article-id pub-id-type="doi">10.2214/AJR.16.16181</article-id><article-id pub-id-type="manuscript">NIHMS791904</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Dual PET and Near-Infrared Fluorescence Imaging Probes as Tools for Imaging in Oncology</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>An</surname><given-names>Fei-Fei</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Mark</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kommidi</surname><given-names>Harikrishna</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ting</surname><given-names>Richard</given-names></name></contrib></contrib-group><aff id="A1"><label>1</label>Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, 413 E 69th St, New York, NY, 10065</aff><author-notes><corresp id="CR1">Address correspondence to R. Ting (<email>rct2001@med.cornell.edu</email>).</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>3</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>25</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>8</month><year>2016</year></pub-date><volume>207</volume><issue>2</issue><fpage>266</fpage><lpage>273</lpage><pmc-comment>elocation-id from pubmed: 10.2214/AJR.16.16181</pmc-comment>
<abstract><sec id="S1"><title>OBJECTIVE</title><p id="P1">The purpose of this article is to summarize advances in PET fluorescence resolution, agent design, and preclinical imaging that make a growing case for clinical PET fluorescence imaging.</p></sec><sec id="S2"><title>CONCLUSION</title><p id="P2">Existing SPECT, PET, fluorescence, and MRI contrast imaging techniques are already deeply integrated into the management of cancer, from initial diagnosis to the observation and management of metastases. Combined positron-emitting fluorescent contrast agents can convey new or substantial benefits that improve on these proven clinical contrast agents.</p></sec></abstract><kwd-group><kwd>cancer</kwd><kwd>contrast medium</kwd><kwd>fluorescence</kwd><kwd>multimodality imaging</kwd><kwd>PET</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0037029 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0037029 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |